Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Primary adrenal insufficiency [Addison's disease (AD)] is rare, and systematic studies are few, mostly conducted on small patient samples. We aimed to determine the clinical, immunological, and genetic features of a national registry-based cohort. DESIGN: Patients with AD identified through a nationwide search of diagnosis registries were invited to participate in a survey of clinical features, health-related quality of life (HRQoL), autoantibody assays, and human leukocyte antigen (HLA) class II typing. RESULTS: Of 664 registered patients, 64% participated in the study. The prevalence of autoimmune or idiopathic AD in Norway was 144 per million, and the incidence was 0.44 per 100,000 per year (1993-2007). Familial disease was reported by 10% and autoimmune comorbidity by 66%. Thyroid disease was most common (47%), followed by type 1 diabetes (12%), vitiligo (11%), vitamin B12 deficiency (10%), and premature ovarian insufficiency (6.6% of women). The mean daily treatment for AD was 40.5 mg cortisone acetate and 0.1 mg fludrocortisone. The mean Short Form 36 vitality scores were significantly diminished from the norm (51 vs. 60), especially among those with diabetes. Concomitant thyroid autoimmunity did not lower scores. Anti-21-hydroxylase antibodies were found in 86%. Particularly strong susceptibility for AD was found for the DR3-DQ2/ DRB1*0404-DQ8 genotype (odds ratio, 32; P = 4 x 10(-17)), which predicted early onset. CONCLUSIONS: AD is almost exclusively autoimmune, with high autoimmune comorbidity. Both anti-21-hydroxylase antibodies and HLA class II can be clinically relevant predictors of AD. HRQoL is reduced, especially among diabetes patients, whereas thyroid disease did not have an impact on HRQoL. Treatment modalities that improve HRQoL are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, in a large Norwegian study, approximately 40% of patients with Addison’s disease had a delay in diagnosis of greater than 6 months from the onset of their symptoms, with 64% of the patients diagnosed only after an acute hospital admission.14”
From Adrenal crisis: prevention and management in adult patients (2019) · cites this paper as [14]
In the citing paper
“the majority of patients are only diagnosed during an acute hospital admission, 14”
From Home waking salivary cortisone to screen for adrenal insufficiency (2023) · cites this paper as [14]
Citations
Cites
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk
Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., Mychaleckyj, J. C., Todd, J. A., Bonella, P., Fear, A. L., et al. (2008) · Diabetes · doi:10.2337/db07-1331 · Cited by 790 · cited 1×
“DRB1 and DQB1 genotyping was performed with a PCR-based sequence-specific oligonucleotide probe system at four-digit resolution as described elsewhere (23).”
MethodSelf-citationShort Form 36 (SF-36) health survey: normative data from the general Norwegian population
HÅvard Loge, J., & Kaasa, S. (1998) · Scandinavian Journal of Social Medicine · doi:10.1177/14034948980260040401 · Cited by 565
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 3×
“Indeed,one study found increasedcardiovascular mortality (13), whereas we did not find this association (15).”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 2×
“This suggests that determination of HLA class II genotype should be included in the assessment of patients with 21-hydroxlase antibodies (31).”
BackgroundAnti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
Meager, A., Visvalingam, K., Peterson, P., Möll, K., Murumägi, A., Krohn, K., Eskelin, P., Perheentupa, J., Husebye, E., Kadota, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030289 · Cited by 453
Self-citation21-hydroxylase, a major autoantigen in idiopathic Addison's disease
Winqvist, O., Karlsson, F. A., & Kämpe, O. (1992) · The Lancet · doi:10.1016/0140-6736(92)91829-w · Cited by 410 · cited 1×
“The presence of circulating autoantibodies against 21-hydroxylase, one of the enzymes participating in steroid biosynthesis in the adrenals (18), is the hallmark of the autoimmune form of the disease.”
BackgroundClinical manifestations and management of patients with autoimmune polyendocrine syndrome type I
Husebye, E. S., Perheentupa, J., Rautemaa, R., & Kämpe, O. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02090.x · Cited by 360 · cited 10×
“The diagnosis of autoimmune Addison’s disease was based on positive autoantibodies against 21-hydroxylase, or the presence of associated autoimmune diseases, or other cases of (non-APS-I) autoimmune Addison’s disease in the family.”
BackgroundInfluentialSelf-citationModified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 1×
“Recent developments of more physiological glucocorticoid replacement therapies such as modified-release hydrocortisone tablets (37) and continuous sc hydrocortisone infusion (38) might improve HRQoL and reduce adverse effects.”
BackgroundHahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282 · cited 3×
“Previous studies in Norway (12), Germany (9, 10), and the United Kingdom (11) have reproducibly shown impaired HRQoL in patients with Addison’s disease, particularly reduced vitality and general health perception, and reduced physical functioning in women.”
BackgroundADDISON'S DISEASE – CLINICAL STUDIES. A REPORT OF 108 CASES
Nerup, J. (1974) · Acta Endocrinologica · doi:10.1530/acta.0.0760127 · Cited by 260 · cited 3×
“The female to male ratio in the survey was 1.8, which is comparable to our earlier report (8) and to those from Italy (2), the United Kingdom (3, 4), and Denmark (6).”
ResultInfluentialSubjective health status in Norwegian patients with Addison’s disease.
Løvås, K., Loge, J. H., & Husebye, E. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01466.x · Cited by 256 · cited 6×
“Addison’s Disease in Norway J Clin Endocrinol Metab, December 2009, 94(12):4882–4890”
BackgroundInfluentialSelf-citationMah, P. M., Jenkins, R. C., Rostami‐Hodjegan, A., Newell‐Price, J., Doane, A., Ibbotson, V., Tucker, G. T., & Ross, R. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02106.x · Cited by 243 · cited 1×
“Weight-related dosing (34), timed curves of salivary cortisol (35), and a systematic clinical evaluation (36) should enable many patients to reduce their daily doses.”
BackgroundBensing, S., Brandt, L., Tabaroj, F., Sjöberg, O., Nilsson, B., Ekbom, A., Blomqvist, P., & Kämpe, O. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03340.x · Cited by 242 · cited 1×
“Furthermore, an approximately 2-fold increase in all-cause mortality has been found (13, 14), particularly among young males (15).”
BackgroundErichsen, M. M., Løvås, K., Fougner, K. J., Svartberg, J., Hauge, E. R., Bollerslev, J., Berg, J. P., Mella, B., & Husebye, E. S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0550 · Cited by 240 · cited 4×
“Indeed,one study found increasedcardiovascular mortality (13), whereas we did not find this association (15).”
BackgroundInfluentialSelf-citationKerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanesh, A., & Rogol, A. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501158 · Cited by 228 · cited 1×
“On the other hand, despite expert follow-up, the majority of the patients still use higher than recommended doses of glucocorticoids based on endogenous production (31, 32).”
BackgroundPlat, L., Leproult, R., L’Hermite-Baleriaux, M., Fery, F., Mockel, J., Polonsky, K. S., & Van Cauter, E. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5978 · Cited by 225 · cited 1×
“This may have detrimental metabolic long-term effects (16) and may increase insulin resistance (33).”
BackgroundEighty‐six cases of Addison's disease
Kong, M., & Jeffcoate, W. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02790.x · Cited by 225
High prevalence and increasing incidence of Addison's disease in western Norway
Løvås, K., & Husebye, E. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.t01-1-01552.x · Cited by 222 · cited 3×
“Addison’s disease is rare, with reported prevalence in European countries at approximately 100 per million inhabitants (2–4), although prevalence is somewhat higher in Scandinavia (140 per million) (5).”
BackgroundInfluentialSelf-citationWolff, A. S. B., Erichsen, M. M., Meager, A., Magitta, N. F., Myhre, A. G., Bollerslev, J., Fougner, K. J., Lima, K., Knappskog, P. M., & Husebye, E. S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1873 · Cited by 219 · cited 10×
“The diagnosis of autoimmune Addison’s disease was based on positive autoantibodies against 21-hydroxylase, or the presence of associated autoimmune diseases, or other cases of (non-APS-I) autoimmune Addison’s disease in the family.”
BackgroundInfluentialSelf-citationIs the Prevalence of Addison's Disease Underestimated?
Laureti, S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.5.1762 · Cited by 212
Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial
Gurnell, E. M., Hunt, P. J., Curran, S. E., Conway, C. L., Pullenayegum, E. M., Huppert, F. A., Compston, J. E., Herbert, J., & Chatterjee, V. K. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1134 · Cited by 189
Premature ovarian failure: autoimmunity and natural history
Betterle, C., Rossi, A., Pria, S. D., Artifoni, A., Pedini, B., Gavasso, S., & Caretto, A. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb01748.x · Cited by 187
Plat, L. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.9.3082 · Cited by 177
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone
Løvås, K., Gjesdal, C. G., Christensen, M., Wolff, A. B., Almås, B., Svartberg, J., Fougner, K. J., Syversen, U., Bollerslev, J., Falch, J. A., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0880 · Cited by 163 · cited 3×
“Novel parameters of glucocorticoid action are needed to optimize dosing (16).”
BackgroundSelf-citationMyhre, A. G., Undlien, D. E., Løvås, K., Uhlving, S., Nedrebø, B. G., Fougner, K. J., Trovik, T. S., Sørheim, J. I., & Husebye, E. S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.618 · Cited by 160 · cited 5×
“The highest risk is associated with human leukocyte antigen (HLA) DRB1*03-DQA1*05-DQB1*02 (DR3-DQ2) and DRB1*04-DQA1*03-DQB1*0302 (DR4-DQ8), particularlytothegenotypeDR3-DQ2/DRB1*0404-DQ8,whichis quite specific for autoimmune Addison’s disease (8, 17).”
BackgroundResultInfluentialSelf-citationContinuous subcutaneous hydrocortisone infusion in Addison’s disease
Løvås, K., & Husebye, E. S. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0052 · Cited by 155 · cited 1×
“Recent developments of more physiological glucocorticoid replacement therapies such as modified-release hydrocortisone tablets (37) and continuous sc hydrocortisone infusion (38) might improve HRQoL and reduce adverse effects.”
BackgroundSelf-citationThe prevalence of Addison's disease in Coventry, UK
Willis, A. C., & Vince, F. P. (1997) · Postgraduate Medical Journal · doi:10.1136/pgmj.73.859.286 · Cited by 150
Yu, L., Brewer, K. W., Gates, S., Wu, A., Wang, T., Babu, S. R., Gottlieb, P. A., Freed, B. M., Noble, J., Erlich, H. A., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5414 · Cited by 149
Self-citationArlt, W., Rosenthal, C., Hahner, S., & Allolio, B. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02473.x · Cited by 144 · cited 1×
“Weight-related dosing (34), timed curves of salivary cortisol (35), and a systematic clinical evaluation (36) should enable many patients to reduce their daily doses.”
BackgroundLaureti, S., Casucci, G., Santeusanio, F., Angeletti, G., Aubourg, P., & Brunetti, P. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.2.8636252 · Cited by 101 · cited 1×
“Addison’s disease rarely presented before 10 yr of age, and when diagnosed in childhood it is usually part of APS-I (19, 26) or adrenoleukodystrophy (27).”
BackgroundBleicken, B., Hahner, S., Loeffler, M., Ventz, M., Allolio, B., & Quinkler, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0578 · Cited by 101 · cited 2×
“Previous studies in Norway (12), Germany (9, 10), and the United Kingdom (11) have reproducibly shown impaired HRQoL in patients with Addison’s disease, particularly reduced vitality and general health perception, and reduced physical functioning in women.”
BackgroundFalorni, A., Laureti, S., De Bellis, A., Zanchetta, R., Tiberti, C., Arnaldi, G., Bini, V., Beck-Peccoz, P., Bizzarro, A., Dotta, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030954 · Cited by 93
Prà, C. D., Chen, S., Furmaniak, J., Smith, B. R., Pedini, B., Moscon, A., Zanchetta, R., & Betterle, C. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480565 · Cited by 91 · cited 1×
“SCC antibodies were predominantly found in women, and the presence was associated with premature ovarian insufficiency (29, 30).”
BackgroundOftedal, B. E., Wolff, A. S. B., Bratland, E., Kämpe, O., Perheentupa, J., Myhre, A. G., Meager, A., Purushothaman, R., Ten, S., & Husebye, E. S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.002 · Cited by 89
Self-citationYu, L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.328 · Cited by 82
Aamodt, G., Stene, L. C., Njølstad, P. R., Søvik, O., Joner, G., & for the The Norwegian Childhood Diabetes Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1568 · Cited by 53
Løvås, K., Thorsen, T. E., & Husebye, E. S. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344183 · Cited by 46 · cited 1×
“Weight-related dosing (34), timed curves of salivary cortisol (35), and a systematic clinical evaluation (36) should enable many patients to reduce their daily doses.”
BackgroundSelf-citationWolff, A. S. B., Oftedal, B. E., Johansson, S., Bruland, O., Løvås, K., Meager, A., Pedersen, C. B., Husebye, E. S., & Knappskog, P. M. (2008) · Genes and Immunity · doi:10.1038/sj.gene.6364457 · Cited by 40 · cited 1×
“in APS-I patients, anti-interferon antibody assay (24, 25)”
Self-citation
Cited by
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Autoimmune Polyendocrine Syndromes
Husebye, E. S., Anderson, M. S., & Kämpe, O. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1713301 · Cited by 466
Self-citationDiagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Dynamics of ACTH and Cortisol Secretion and Implications for Disease
Lightman, S. L., Birnie, M. T., & Conway-Campbell, B. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa002 · Cited by 439
Husebye, E. S., Allolio, B., Arlt, W., Badenhoop, K., Bensing, S., Betterle, C., Falorni, A., Gan, E. H., Hulting, A. ‐., Kasperlik‐Zaluska, A., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12162 · Cited by 403
Self-citation
Metadata
- Authors
- Erichsen, M. M., Løvås, K., Skinningsrud, B., Wolff, A. B., Undlien, D. E., Svartberg, J., Fougner, K. J., Berg, T. J., Bollerslev, J., Mella, B., Carlson, J. A., Erlich, H., & Husebye, E. S.
- Affiliations
- Haukeland University Hospital (NO)
- Department of Medicine (M.M.E., K.L., E.S.H.), Haukeland University Hospital, N-5021 Bergen, Norway
- Oslo University Hospital (NO)
- Institute of Medicine (K.L., A.B.W., E.S.H.), University of Bergen, N-5007 Bergen, Norway
- University Hospital of North Norway (NO)
- St Olav's University Hospital (NO)
- Østfold Hospital Trust (NO)
- Clinical Chemistry (J.A.C.), University Hospital, S-205 05 Malmö, Sweden
- Roche Molecular Systems (H.E.), Alameda, California 94501
- Corresponding author
- Erichsen, Martina M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-12-01
- Volume
- 94
- Issue
- 12
- Pages
- 4882-4890
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2135257181
- Cited by
- 422
- References
- 41
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 33 · 2023: 34 · 2022: 28 · 2021: 33 · 2020: 34 · 2019: 22 · 2018: 16 · 2017: 22 · 2016: 30 · 2015: 19 · 2014: 38 · 2013: 19 · 2012: 23
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- Addison's disease, HLA class II, HLA-DR3-DQ2, autoimmune disease comorbidity, thyroid autoimmunity, type 1 diabetes, health-related quality of life, corticosteroid therapy, familial disease, incidence and prevalence
- MeSH terms
- Addison Disease, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Autoantibodies, Autoimmune Diseases, DNA, Employment, Female, Glucocorticoids, Health Surveys, HLA Antigens, Humans, Male, Middle Aged, Norway, Quality of Life, Surveys and Questionnaires, Registries, Hormone Replacement Therapy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.